2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Taliya Lantsman, MD, discusses real-world safety and efficacy data with dostarlimab plus chemotherapy in patients with advanced endometrial cancer.
“At our institution, we give radiation to these patients, which differs from what we saw in RUBY, where radiation was not given. Interestingly enough, none of these patients at time of analysis had disease progression or recurrence.”
Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center, discusses the safety and efficacy of dostarlimab-gxly (Jemperli) plus chemotherapy in patients with advanced endometrial cancer according to findings from a real-world, retrospective, single-institution analysis.
Related Content: